Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women
2013
Background
Antiretrovirals (ARV) that achieve adequate concentrations in anatomical sites of transmission are of interest for HIV prevention. A Phase 1, open label, pharmacokinetic (PK) study was performed to describe first dose and steady-state PK of the integrase inhibitor dolutegravir (DTG) in blood plasma (BP), cervicovaginal fluid (CVF), cervical tissue (CT), and vaginal tissue (VT) in HIV-1 negative women.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
29
Citations
NaN
KQI